Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent Journal Article
| Authors: | Gold, J. S.; Jaques, D. P.; Bentrem, D. J.; Shah, M. A.; Tang, L. H.; Brennan, M. F.; Coit, D. G. |
| Article Title: | Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent |
| Abstract: | Background: Metastatic gastric cancer has a dismal prognosis. We identified a subset of patients where surgical resection with therapeutic intent was undertaken in the setting of known metastatic disease. Methods: Review of a prospectively maintained database of gastric cancer patients at a single institution over a 19-year period was performed. Results: Thirty-seven patients with metastatic disease known prior to resection with therapeutic intent were identified out of 3384 patients with gastric cancer (1%). Twelve patients had positive peritoneal cytology as the only evidence of metastasis, 21 had gross metastasis limited to peritoneal surfaces, one had peritoneal and ovarian metastasis, one had liver metastasis, one had retropancreatic lymph node metastasis, and one had a malignant pleural effusion. Thirty-six patients (97%) received chemotherapy prior to resection, and 30 (81%) received postoperative chemotherapy. The median time from diagnosis to resection was 4.5 months (range 1-22) in patients receiving preoperative chemotherapy. Median survival was 12 months after resection with no three-year survivors. Predictors of worse prognosis were cytologic or pathologic evidence of persistent metastatic disease at the time of resection or at laparoscopy within six weeks of resection (P < .01), N3 disease (P = .03), and total gastrectomy or additional organ resection (P = .04). Metastatic disease as evidenced by cytology only was not associated with improved prognosis. Conclusions: Highly selected patients with metastatic gastric cancer undergoing surgical resection with therapeutic intent have a relatively poor prognosis. Persistent detectable metastatic disease after preoperative chemotherapy portends a particularly poor prognosis. © 2006 Society of Surgical Oncology. |
| Keywords: | adult; cancer survival; treatment outcome; aged; middle aged; cancer surgery; survival rate; retrospective studies; major clinical study; cisplatin; doxorubicin; fluorouracil; patient selection; antineoplastic agents; capecitabine; paclitaxel; cancer patient; chemotherapy, adjuvant; chemotherapy; methotrexate; lymph node metastasis; laparoscopy; prospective study; lymph node excision; cytology; abdominal abscess; docetaxel; irinotecan; survival time; length of stay; liver metastasis; folinic acid; surgery; gastrectomy; surgical mortality; stomach cancer; pleura effusion; visceral metastasis; ovary metastasis; resection; external beam radiotherapy; preoperative treatment; floxuridine; wound infection; peritoneum metastasis; stomach neoplasms; wound dehiscence; infection complication; metastatic; gastric cancer; anastomosis leakage |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 14 |
| Issue: | 2 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2007-02-01 |
| Start Page: | 365 |
| End Page: | 372 |
| Language: | English |
| DOI: | 10.1245/s10434-006-9059-z |
| PUBMED: | 17146744 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: ASONF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work